ctDNA blood test monitoring after pancreatic cancer surgery
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study looks at whether a special blood test (ctDNA) can detect tiny amounts of pancreatic cancer left after surgery. It may help doctors monitor who is at higher risk of cancer coming back, so they can tailor follow-up and treatment timing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had pancreatic cancer surgery with an intent to cure, and the surgeon removed all or nearly all visible tumor (R0 or R1).
- You are 18 or older, and you can participate regardless of sex.
- Your general health is good enough for daily activities (ECOG score 0–2).
- You are expected to live at least 3 months.
- Your pancreatic cancer diagnosis is ductal adenocarcinoma (not another type).
- You did not receive anti-cancer medicines before starting the first round of chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a blood test (ctDNA, a DNA signal from tumors) can help track how pancreatic cancer responds during planned conversion therapy. It may help doctors spot treatment response earlier and guide next steps.
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
This trial uses a blood test to find tiny bits of tumor DNA after treatment. It helps doctors see if any cancer remains, which could guide next steps for people with esophageal, stomach, or pancreatic cancer.
This pilot study checks whether a special blood test (ctDNA) can detect cancer signals and work as well as another sample method during biopsies for liver, bile duct, or pancreatic cancers. It may help doctors choose the best way to confirm the diagnosis from biopsy samples.
This trial uses a blood test (called cfDNA) to look for early signs of pancreatic cancer. It compares results from people with pancreatic cancer, precancerous changes, non-cancerous pancreatic conditions, and healthy individuals to improve early detection.
This study looks at DNA signals from blood tests (so-called “ctDNA” and another type of DNA test) in people with early-stage pancreatic cancer. It aims to see whether these tests can help track cancer after surgery and check for signs of return.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.